Not Yet Recruiting
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
NCT07662720
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +12 more
- Locations
-
Not specified